 Merck & Co. said Thursday that a pair of its hepatitis C virus treatments showed a cure rate of 98% in a mid-stage trial, supporting advancement of the study.. The drug maker said it has initiated a Phase 3 trial after analyzing the study results of the 12-week regimen using the oral treatment, which combines MK-5172 and MK-8742. The company said the study also showed a 94% cure rate for patients receiving those treatments, plus ribavirin.